Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Bradley CJ, Dahman B, Jagsi R, Katz S, Hawley S (2015) Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer. Breast Cancer Res Treat 154(2):417–422CrossRefPubMed
2.
Reynolds KL, Higgins MJ (2013) Endocrine therapy for breast cancer: a tough pill to swallow. Menopause 20(7):714–716CrossRefPubMed
3.
Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128CrossRefPubMedPubMedCentral
Metadata
Title
Compliance with hormonal therapy
Authors
Henry J. Carson
Chirantan Ghosh
Publication date
01-05-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3813-0

Other articles of this Issue 1/2016

Breast Cancer Research and Treatment 1/2016 Go to the issue

Clinical trial

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Review

Potential of breastmilk analysis to inform early events in breast carcinogenesis: rationale and considerations

Preclinical study

Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown

Epidemiology

Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes

Epidemiology

Ethnic differences in the relationships between diabetes, early age adiposity and mortality among breast cancer survivors: the Breast Cancer Health Disparities Study

Preclinical Study

Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits